ProKidney (PROK) director awarded 135K stock options as compensation

Rhea-AI Filing Summary

PROKIDNEY CORP. director William F. Doyle reported receiving a grant of stock options as part of non-employee director compensation. He was awarded 135,000 director stock options, each allowing him to buy one share of Class A Common Stock at an exercise price of $1.81 per share.

The options were granted at no upfront cost and will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual general shareholder meeting. After this grant, Doyle holds 135,000 options directly, with an expiration date in 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DOYLE WILLIAM F

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director stock option (right to buy)	135,000	$0.00	--

Holdings After Transaction: Director stock option (right to buy) — 135,000 shares (Direct, null)

Footnotes (1)

1. These options were granted under the Issuer's non-employee director compensation policy. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

Key Figures

Options granted: 135,000 options Exercise price: $1.81 per share Underlying shares: 135,000 shares +2 more

5 metrics

Options granted 135,000 options Director award on 2026-05-28

Exercise price $1.81 per share Director stock option grant

Underlying shares 135,000 shares Class A Common Stock underlying options

Post-grant option holdings 135,000 options Total options following this grant

Option expiration date May 28, 2036 End of option term

Key Terms

Director stock option (right to buy), non-employee director compensation policy, vest in full, annual general shareholder meeting

4 terms

Director stock option (right to buy) financial

"security_title: Director stock option (right to buy)"

non-employee director compensation policy financial

"These options were granted under the Issuer's non-employee director compensation policy."

vest in full financial

"The options will vest in full on the sooner of the one-year anniversary"

annual general shareholder meeting financial

"or the date of Company's next annual general shareholder meeting."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOYLE WILLIAM F

(Last) (First) (Middle)

C/O PROKIDNEY CORP

2000 FRONTIS PLAZA BLVD, SUITE 250

(Street)

WINSTON SALEM NORTH CAROLINA 27103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director stock option (right to buy)	$1.81	05/28/2026		A		135,000(1)		(2)	05/28/2036	Class A Common Stock	135,000	$0	135,000	D

Explanation of Responses:

1. These options were granted under the Issuer's non-employee director compensation policy.

2. The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.

	/s/ Todd Girolamo, attorney in fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did the latest Form 4 for PROK reveal about director William F. Doyle?

The Form 4 shows director William F. Doyle received 135,000 stock options in PROKIDNEY CORP. These options are part of the non-employee director compensation policy and give him the right to buy Class A Common Stock at a set exercise price.

How many stock options did William F. Doyle receive from PROK (ProKidney)?

William F. Doyle received a grant of 135,000 director stock options from PROKIDNEY CORP. Each option corresponds to one share of Class A Common Stock, providing equity-based compensation aligned with the company’s non-employee director compensation policy and long-term shareholder interests.

What is the exercise price of William F. Doyle’s PROKIDNEY stock options?

The granted options have an exercise price of $1.81 per share for PROKIDNEY Class A Common Stock. This means Doyle can purchase shares at $1.81 once the options vest, regardless of the market price at the time of exercise, until the options expire.

When do William F. Doyle’s PROK director stock options vest?

The options will vest in full on the earlier of the one-year anniversary of the grant date or PROKIDNEY’s next annual general shareholder meeting. This single vesting event structure provides Doyle with full exercisability after that specified time or corporate milestone occurs.

When do the newly granted PROKIDNEY options to William F. Doyle expire?

The options granted to William F. Doyle expire in 2036, specifically on May 28, 2036. After that expiration date, any unexercised options will no longer be valid, so Doyle must exercise vested options before this long-term deadline to acquire shares.

Did William F. Doyle buy or sell PROK shares on the open market in this Form 4?

The Form 4 reports a grant of stock options as compensation, not an open-market purchase or sale of PROK shares. Doyle acquired derivative securities at no cash cost, reflecting an equity award rather than a discretionary trading transaction in the market.